AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 31 min read$DNLI

Schuth Alexander O. sold $65K of DNLI

Schuth Alexander O. (COFO and Secretary) sold 2,768 shares of Denali Therapeutics Inc. (DNLI) at $23.44 on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schuth Alexander O.
Published Sep 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 7:15 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$DNLI
Neutral
high confidence
Mentioned
$DNLI
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DNLINeutralLow
01

Why it matters

The filing provides a factual record of the insider's share disposition without additional commentary.

02

Market read

A routine insider sale with limited material impact on the stock.

03

What to watch

Potential upcoming clinical trial results that insiders may be aware of.

Relevance 2/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$DNLINeutralHigh confidence
Context

Officer Alexander Schuth sold 2,768 shares for $64,882 via a 10b5‑1 plan on 2026‑09‑01.

Expected impact

Minimal short‑term price pressure; no significant move expected.

Evidence & confidence

The transaction amount is small relative to total holdings and typical insider sales, and no accompanying corporate news was disclosed.

Market effects

Sector

None; biotech sector unchanged.

Regional

No regional effect.

Global

Insignificant.

Counterpoint

What could challenge this read

The sale could be a pre‑emptive move ahead of undisclosed negative news.

Key entities

  • Company
    Denali Therapeutics Inc.

    Biotech firm developing therapies for neurodegenerative diseases.

  • Individual
    Alexander Schuth

    Chief Financial Officer and Secretary of Denali Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DNLI insider trading history →

Related articles

AUG 13
$DNLIMedAI 8/10

Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics (DNLI) reported Q2 2026 net product revenue of $3.6 million from the first full quarter of AVLAYAH in the US. It guided Q3 revenue to $10 million to $12 million and said pro forma cash and securities were $1.1 billion after a $195 million priority review voucher sale. R&D was $97.0 million; net loss was $127.6 million.

fool.com6 min
AUG 6
$DNLIMed

Denali Therapeutics Inc. (DNLI): Results of Operations and Financial Condition

Denali Therapeutics Inc. (DNLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights • Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue • Advanced TransportVehicle™ portfolio with two Alzheimer’s

SEC EDGAR 8-K6 min
JUL 28
$DNLIMed

Denali Therapeutics Inc. (DNLI): Completion of Acquisition or Disposition of Assets

Denali Therapeutics Inc. (DNLI) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. dnli-20260727 0001714899 FALSE 0001714899 2026-07-27 2026-07-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

SEC EDGAR 8-K2 min
JUL 14
$BIIBMed

New experimental Alzheimer's drug shows potential after study shows slower cognitive decline

Biogen reported at the Alzheimer’s Association International Conference that its experimental antisense drug diranersen, given via spinal injection, slowed cognitive decline in a subset of about 400 participants with mild cognitive impairment or mild Alzheimer’s. In one lowest-dose test, results showed a 26% reduction in decline versus placebo. Biogen plans a larger study; side effects included injection pain and temporary confusion.

fortune.com6 min